AKT3 and acute myeloid leukemia: Since the ELN-2017 score is based on the nature of the genetic alterations found in AML samples and because AKT3 expression is significantly higher in the adverse group than in the favorable and intermediate groups, it was probable that some of these genetic abnormalities could be either correlated or anti-correlated to the level of AKT3 expression.